Permanne B, Sand A, Ousson S, N xe9 ny M, Hantson J, Schubert R, et al. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies. ACS Chem Neurosci. 2022;13:1296-1314 pubmed publisher

Natarajan C, Cook C, Ramaswamy K, Krishnan B. Phospholipase D1 Attenuation Therapeutics Promotes Resilience against Synaptotoxicity in 12-Month-Old 3xTg-AD Mouse Model of Progressive Neurodegeneration. Int J Mol Sci. 2023;24: pubmed publisher

Shao E, Chang C, Li Z, Yu X, Ho K, Zhang M, et al. TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviors in a Dravet syndrome model. Sci Transl Med. 2022;14:eabm5527 pubmed publisher

Abdelhamid M, Zhou C, Ohno K, Kuhara T, Taslima F, Abdullah M, et al. Probiotic Bifidobacterium breve Prevents Memory Impairment Through the Reduction of Both Amyloid-β Production and Microglia Activation in APP Knock-In Mouse. J Alzheimers Dis. 2022;85:1555-1571 pubmed publisher

Choi Y, Dunn Meynell A, Marchese M, Blumberg B, Gaindh D, Dowling P, et al. Erythropoietin-derived peptide treatment reduced neurological deficit and neuropathological changes in a mouse model of tauopathy. Alzheimers Res Ther. 2021;13:32 pubmed publisher

Montalbano M, McAllen S, Cascio F, Sengupta U, Garcia S, Bhatt N, et al. TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia. Neurobiol Dis. 2020;146:105130 pubmed publisher

Lo Cascio F, Garcia S, Montalbano M, Puangmalai N, McAllen S, Pace A, et al. Modulating disease-relevant tau oligomeric strains by small molecules. J Biol Chem. 2020;295:14807-14825 pubmed publisher

Puangmalai N, Bhatt N, Montalbano M, Sengupta U, Gaikwad S, Ventura F, et al. Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer's disease, progressive supranuclear palsy and dementia with Lewy bodies. Cell Death Dis. 2020;11:314 pubmed publisher

Sengupta U, Puangmalai N, Bhatt N, Garcia S, Zhao Y, Kayed R. Polymorphic α-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein. Mol Neurobiol. 2020;57:2741-2765 pubmed publisher

Lo Cascio F, Puangmalai N, Ellsworth A, Bucchieri F, Pace A, Palumbo Piccionello A, et al. Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives. Sci Rep. 2019;9:19011 pubmed publisher

Franklin W, Krishnan B, Taglialatela G. Chronic synaptic insulin resistance after traumatic brain injury abolishes insulin protection from amyloid beta and tau oligomer-induced synaptic dysfunction. Sci Rep. 2019;9:8228 pubmed publisher

Guix F, Corbett G, Cha D, Mustapic M, Liu W, Mengel D, et al. Detection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles. Int J Mol Sci. 2018;19: pubmed publisher

Sengupta U, Portelius E, Hansson O, Farmer K, Castillo Carranza D, Woltjer R, et al. Tau oligomers in cerebrospinal fluid in Alzheimer's disease. Ann Clin Transl Neurol. 2017;4:226-235 pubmed publisher

Kim H, Moon S, Kim S, Lee M, Suk M, Park D, et al. Chronological changes in the expression of phosphorylated tau and 5‑AMP‑activated protein kinase in the brain of senescence‑accelerated P8 mice. Mol Med Rep. 2017;15:3301-3309 pubmed publisher

Liechtenstein T, Perez Janices N, Blanco Luquin I, Goyvaerts C, Schwarze J, Dufait I, et al. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology. 2014;3:e945378 pubmed